Three quick details:
1. AcelRx plans to use the senior secured debt facility with Oxford Finance to commercially launch DSUVIA and repay $9 million outstanding under a previous senior credit facility.
2. DSUVIA is a sufentanil sublingual tablet indicated for the management of acute pain severe enough to require an opioid analgesic.
3. AcelRx is hiring hospital account managers to field interest in DSUVIA from hospitals, ASCs and government entities, CEO Vince Angotti said in a press release.
More articles on supply chain:
ASC supply chain tip of the day: Focus on case costing
HCA Healthcare affiliate acquires supply chain management company — 4 insights
3 key opportunities for success in the ASC market
